Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
about
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptorsAn Integrative Perspective on the Role of Dopamine in SchizophreniaNeuroleptic-induced deficit syndrome in bipolar disorder with psychosisAmotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.Hypothesis: grandiosity and guilt cause paranoia; paranoid schizophrenia is a psychotic mood disorder; a review.Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.Antipsychotics and amotivationPharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports.Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis.Are psychiatric diagnoses of psychosis scientific and useful? The case of schizophrenia.Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.The Psychosis Continuum: Testing a Bifactor Model of Psychosis in a General Population Sample.Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.Correspondence between negative symptoms and potential sources of secondary negative symptoms over time.Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.Average duration of treatment with antipsychotics among concession card holders in Australia.Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial.Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteersEthics of giving antipsychotic medication to at-risk young peopleEngaging People with Psychosis in Acceptance and Commitment Therapy and MindfulnessEffects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy
P2860
Q28273285-F9E14619-16CE-43AB-9E90-AAEB9D4DB5B1Q33839379-B95BB777-8C3F-4121-A43E-C8E7F3692E65Q34046221-6239F2E3-AEE6-4B5A-8B49-A5C73791277CQ34322992-9E8D99B8-8304-48CE-A787-4508BBB77C29Q34721160-57FDCD59-E82B-4008-84C0-FB874B6B98AAQ34996934-D0B97C61-FC80-45FD-9ECB-5D9AC0C974D3Q35421296-87B3E791-AB28-4D42-8817-A383A7D42D35Q36715888-09F7F3E0-C982-46BA-9B99-5183DF9F0D9BQ37078959-41BD8A47-28AD-4B7E-B0C8-9B443082B9F9Q37647927-E5C53DCD-415D-4449-813A-B7F8FAB1E626Q37773355-B1DFA6AC-A4BF-4AB1-9549-CE8A84C5BF9CQ38815384-8DCB6009-F4E5-4778-816E-1DED6B353133Q38836831-71087C26-90CE-4476-BCD0-1585E1F6530EQ39739268-616453FF-AEE5-4F61-8A15-C1C437EFB75CQ41656833-3F762EA2-6CEA-4F4C-A35E-07CDE0118094Q46640313-84D36A14-B964-45E7-86E7-0CEC23174D90Q47556225-549F7B82-512E-488E-AABC-17DB014DE45BQ47586487-42C5F40F-6597-42A1-B9C0-F6FE1932AF35Q47973225-30992277-20C8-47B4-82E9-41E2B8A4E084Q50479302-56C94114-581F-4506-82B9-471FEB210CA3Q50757787-6E72124F-6AEA-4252-B62B-EDCA39C6A24FQ57602651-FDE9C67C-369B-41DB-BF1A-53866BDA080AQ57810372-34E7489A-F0E6-4561-A0D9-65A7C35EE7EDQ57892499-8DCF00CC-FA84-441E-AF94-80B1EE90389FQ57978272-A2715293-3471-4AA5-98EB-765AF29EAE75
P2860
Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Negative signs and symptoms se ...... eridone in healthy volunteers.
@ast
Negative signs and symptoms se ...... eridone in healthy volunteers.
@en
Negative signs and symptoms se ...... eridone in healthy volunteers.
@nl
type
label
Negative signs and symptoms se ...... eridone in healthy volunteers.
@ast
Negative signs and symptoms se ...... eridone in healthy volunteers.
@en
Negative signs and symptoms se ...... eridone in healthy volunteers.
@nl
prefLabel
Negative signs and symptoms se ...... eridone in healthy volunteers.
@ast
Negative signs and symptoms se ...... eridone in healthy volunteers.
@en
Negative signs and symptoms se ...... eridone in healthy volunteers.
@nl
P2093
P1476
Negative signs and symptoms se ...... eridone in healthy volunteers.
@en
P2093
Adrienne Lahti
Ana Pascual
Javier Sanz
Juan Francisco Artaloytia
Pedro Cubero
Tomás Palomo
P304
P356
10.1176/APPI.AJP.163.3.488
P407
P577
2006-03-01T00:00:00Z